Company: BWNB
Filing Date: 2025-11-05
Form Type: 424B5
Source: 0001104659-25-106685
Chunk: 49

Company: Babcock & Wilcox Enterprises, Inc.
Filing Date: 2025-11-05
Form: 424B5
Chunk 49
---
 capital requirements, our financial condition, and other factors
our board of directors deems relevant.

<div align='center'>S-30

PLAN OF DISTRIBUTION</div>

The Agents are acting
as our sales agents in connection with the offer and sale of our Common Stock pursuant to this prospectus supplement. Upon written
instructions from us, the designated Agent will use its commercially reasonable efforts consistent with its normal sales and trading
practices to sell, as our sales agent, the Common Stock under the terms and subject to the conditions set forth in the Sales
Agreement. We will instruct the designated Agent as to the amount of shares of Common Stock to be sold by it. We may instruct the
Agents not to sell the Common Stock if the sales cannot be effected at or above the price designated by us in any instruction. We or
the Agents may suspend the offering of shares of Common Stock upon proper notice and subject to other conditions.

Sales of the Common Stock,
if any, under this prospectus supplement may be made in transactions that are deemed to be “at the market,” as defined in
Rule 415 under the Securities Act.

The designated Agent will
provide written confirmation of a sale to us no later than the opening of the trading day on the NYSE following each trading day in which
the shares of Common Stock are sold under the Sales Agreement. Each confirmation will include the number of shares of Common Stock sold
on the preceding day, the sales price of the Common Stock sold, the aggregate gross sales proceeds, the net proceeds to us and the compensation
payable by us to the designated Agent in connection with the sales.

The designated Agent will
receive a commission from us equal to 3% of the gross sales price of any shares of Common Stock sold through the designated Agent under
the Sales Agreement. We estimate that the total expenses for the offering, excluding compensation payable to the Agents under the terms
of the Sales Agreement, will be approximately $500,000. This estimate includes the reimbursement by the Company of the reasonable fees
and expenses of the Agents in connection with the transactions contemplated by the Sales Agreement. In addition, we have agreed to reimburse
the Agents for (i) the fees and disbursements of their counsel, payable upon execution of the Sales Agreement, in the amount of $150,000,
and (ii) up to $12,500 per calendar quarter, for ongoing diligence arising from the transactions contemplated by the Sales Agreement.

Settlement for sales of our
Common Stock will occur on